VEGFA and renal cell carcinoma: The therapeutic landscape in locally advanced and metastatic RCC has changed dramatically in the past few years with the introduction of agents that target angiogenesis pathways including tyrosine kinase inhibitors (sunitinib, sorafenib, pazopanib, and axitinib), mTOR inhibitors (temsirolimus and everolimus) and direct vascular endothelial growth factor (VEGF) inhibitors (bevacizumab) [84].